Symptomatic hyperperfusion after combined revascularization surgery in patients with pediatric moyamoya disease: patient series

Yoshio Araki, MD, PhD, Takashi Mamiya, MD, Naotoshi Fujita, PhD, Kinya Yokoyama, MD, PhD, Kenji Uda, MD, PhD, Fumiaki Kanamori, MD, PhD, Kai Takayanagi, MD, Kazuki Ishii, MD, Masahiro Nishihori, MD, PhD, Kazuhiro Takeuchi, MD, PhD, Kuniaki Tanahashi, MD, PhD, Yuichi Nagata, MD, PhD, Yusuke Nishimura, MD, PhD, Takaumi Tanei, MD, PhD, Shinsuke Muraoka, MD, PhD, Takashi Izumi, MD, PhD, Katsuhiko Kato, MD, PhD, and Ryuta Saito, MD, PhD

1Department of Neurosurgery, Nagoya University Graduate School of Medicine, Aichi, Japan; 2Department of Radiological Technology, Nagoya University Hospital, Aichi, Japan; 3Department of Neurosurgery, Komaki City Hospital, Komaki, Aichi, Japan; 4Department of Neurosurgery, Tosei General Hospital, Seto, Aichi, Japan; and 5Functional Medical Imaging, Biomedical Imaging Sciences, Division of Advanced Information Health Sciences, Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Aichi, Japan

BACKGROUND Symptomatic hyperperfusion after cerebral revascularization for pediatric moyamoya disease (MMD) is a rare phenomenon. The authors report a series of patients with this condition.

OBSERVATIONS In all three patients in this case series, the combined revascularization was on the left side, the patency of bypass grafts was confirmed after surgery, and focal hyperemia around the anastomotic site was observed on single photon emission computed tomography (SPECT). On the first to eighth days after surgery, all of the patients developed neurological manifestations, including motor aphasia, cheiro-oral syndrome, motor weakness of their right upper limbs, and severe headaches. These symptoms disappeared completely approximately 2 weeks after surgery, and all patients were discharged from the hospital. Quantitative SPECT was performed to determine the proportional change in cerebral blood flow (ΔRCBF) to ipsilateral cerebellar ratio (denoted ΔRCBF) in the region of interest around the anastomoses, and the mean value was 1.34 (range, 1.29–1.41).

LESSONS This rare condition, which develops soon after surgery, requires an accurate diagnosis by SPECT. One indicator is that the ΔRCBF has risen to 1.3 or higher. Subsequently, strategic blood pressure treatment and fluid management could prevent the development of hemorrhagic stroke.

https://thejns.org/doi/abs/10.3171/CASE2274

KEYWORDS combined revascularization surgery; hyperperfusion; moyamoya disease; transient neurological deficits; pediatrics

Moyamoya disease (MMD) is a rare condition that is characterized by stenotic obstructive changes at the ends of the bilateral internal carotid arteries (ICAs) and the development of basilar collateral networks called moyamoya vessels (MMVs). Direct and indirect combined revascularization surgery has been established as an effective treatment to prevent future stroke. These surgeries consist of a superficial temporal artery (STA)-middle cerebral artery (MCA) bypass for direct bypass and the placement of vascularized pedicles using the temporal muscles, dura mater and periosteum. It has been reported that symptomatic hyperperfusion occurs after this surgery due to the rapid inflow of blood from the direct bypass. This condition occurs relatively frequently, especially in adult patients, and it sometimes follows hemorrhagic conversion and exacerbates the neurological outcome. Therefore,
numerous studies have been conducted on risk occurrence and treatment strategies. However, postoperative symptomatic hyperperfusion rarely develops in pediatric patients with MMD and has not been investigated fully. Here, we describe three cases of pediatric patients with MMD who had specific neurological symptoms after combined revascularization for pediatric MMD, including postoperative courses and treatment strategies.

**Study Description**

From May 2020 to July 2021, three pediatric patients with MMD who underwent surgery at our hospital were retrospectively identified. MMD was diagnosed by magnetic resonance imaging (MRI)/magnetic resonance angiography (MRA) based on the current guidelines. In all three of the patients, surgery was indicated based on the guidelines, and direct and indirect combined revascularization was performed. In this study, data were also extracted from four patients who underwent left-sided combined surgery to compare the characteristics of patients who were postoperatively asymptomatic during the same period with those of the symptomatic cases. The main procedure that was used for direct bypass was the STA-MCA single bypass. The STA graft was harvested by the cut-down technique, and an end-to-side anastomosis was performed on the MCA as a recipient. At our institution, indirect revascularization involves placing the pedicled temporal muscle, peristeum, and galea on the brain surface and suturing them with the inverted dura mater. Encephaloarteriosynangiosis using STA grafts was not performed. In combined revascularization, both the direct and indirect methods were enforced. This surgical technique, which is used in our facility, was described in a previous report. In postoperative imaging, we evaluated the hemorrhagic complications and bypass patency with computed tomography (CT)/computed tomography angiography (CTA) on postoperative day (POD) 1. MRI/MRA was performed on POD 2 to confirm the presence or absence of ischemic stroke and bypass patency. Single photon emission tomography (SPECT), an assessment of cerebral blood flow (CBF), was performed on POD 3. At our facility, $^{99m}$Tc-ethyl cysteinate dimer is used as a radioisotope for pediatric patients. Brain perfusion SPECT studies were performed using a double-head gamma camera (Symbia T or Symbia T6, Siemens Healthcare, Erlangen, Germany). CBF was quantitatively measured by manually defining a 1-cm diameter region of interest (ROI) in the exact vascular territory supplied by the bypass and the ipsilateral cerebellar hemisphere according to a previously reported method (Fig. 1). For the ROI supplied by the bypass, we calculated the radioactivity count divided by that count of the ipsilateral cerebellar ROI. This value was defined as the RCBF. The proportional change in the RCBF (denoted $\Delta$RCBF) within each ROI before surgery and on POD 3 was calculated by dividing the postoperative RCBF by the preoperative RCBF. Table 1 summarizes the characteristics of the three pediatric MMD patients who presented with postoperative symptomatic hyperperfusion (case 1–3) and the four patients who were postoperatively asymptomatic (case 4–7).

**Case 1**

A 12-year-old right-handed girl had transient motor weakness in her left upper limbs. The patient was referred to us for surgical treatment with a diagnosis of MMD. No stroke lesions were found on MRI (Fig. 2A, left). On MRA, the bilateral ICA was highly stenotic at the terminal portion, and the anterior cerebral artery (ACA) and MCA had disappeared (Fig. 2A, right). The MMVs were bilaterally developed, and the posterior cerebral artery (PCA) was not affected.

First, right combined revascularization was performed with an uneventful postoperative course. A left STA-MCA bypass and encephalo-duo-myo-periosteal synangiosis (EDMPS) were performed with any neurological abnormalities just after the surgery. From POD 2, the patient developed a severe headache, cheiro-oral syndrome (COS) on her right side, and motor aphasia, and she was crying. On MRI, a sulcal hyperintensity signal appeared mainly around the anastomotic site on fluid-attenuated inversion recovery (Fig. 2B, left, red dotted ellipse). MRA allowed visualization of the STA graft (Fig. 2B, right, white arrow). On SPECT performed on POD 3, findings of focal hyperemia were observed around the anastomotic site, and the patient was diagnosed with symptomatic hyperperfusion (Fig. 2C, yellow circle). The calculated $\Delta$RCBF was 1.41 (Table 2). The symptoms disappeared by POD 8, and the patient was discharged without any neurological abnormalities. Three months after the operation, MRA showed that a vascular

**Fig. 1.** Original SPECT images that were taken preoperatively and 3 days after surgery (POD 3). CBF was quantitatively measured by manually defining a 1-cm diameter ROI in the exact vascular territory supplied by the bypass and the ipsilateral cerebellar hemisphere (dotted circle). For the ROI that was supplied from the bypass, we calculated the radioactivity count divided by that count of the ipsilateral cerebellar ROI. This value was defined as the RCBF. The proportional change in the RCBF (denoted $\Delta$RCBF) within each ROI before surgery and on POD 3 was calculated by dividing the postoperative RCBF by the preoperative RCBF.
channel from the external carotid (EC) system had developed and that the MMVs on the patient's left side had regressed (Fig. 3, left). No new stroke was found on MRI (Fig. 3, right). The patient's transient ischemic attacks (TIAs) had disappeared.

Case 2
A 9-year-old right-handed boy with MMD developed a headache attack. The patient was diagnosed with MMD by MRI/MRA and referred to us for surgical treatment. Right cerebral revascularization was first performed without any postoperative events. Approximately 5 months after surgery on the right side, left STA-MCA bypass plus EDMPS was performed. Up to POD 1, the patient had no neurological abnormalities, and the bypass was visualized on CTA. From POD 2, the patient presented with right-sided COS and motor aphasia with crying and severe headache. No new stroke was observed on MRI, and the STA graft was visualized on MRA. SPECT on POD 3 showed focal hyperemia around the anastomotic site, so the patient was diagnosed with symptomatic hyperperfusion. The calculated ∆RCBF was 1.29 (Table 2). These symptoms disappeared by POD 8. Three months after the operation, no new stroke was observed on MRI. In MRA, revascularization from the EC system was strongly observed.

Case 3
A right-handed 10-year-old boy developed transient motor weakness in the left upper limbs after crying, and MMD was diagnosed by MRI/MRA. Right STA-MCA bypass plus EDMPS was performed with an uneventful postoperative course. After the first surgery, transient motor weakness of the right limbs appeared. On MRA, stenosis of the left MCA was found to be progressing; therefore, left STA-MCA single bypass plus EDMPS was performed. The bypass was visualized by CTA on POD 1. From that day, along with severe headache, motor weakness on the right hand and aphasia appeared, accompanied by crying and restlessness. SPECT on POD 3 confirmed the findings of focal hyperemia in the left frontoparietal lobe, which was recognized as symptomatic hyperperfusion. The calculated ∆RCBF was 1.32 (Table 2). Symptoms persisted until POD 8 and completely disappeared thereafter. Three months after the operation, the patient had no new stroke events on MRI. On MRA, revascularization from the EC system was strongly observed.

Discussion
Observations
We report three pediatric patients with MMD with postoperative symptomatic hyperperfusion compared to asymptomatic cases.
One of the characteristics of the symptomatic hyperperfusion of the three pediatric MMD cases we experienced was left-sided surgery. There are few reports on postoperative symptomatic hyperperfusion or TNDs in left-sided surgery, and most of them were adult patients. Uchino et al. first showed that the incidence of symptomatic hyperperfusion was significantly higher among adults (31.5%) than among children (5%). They noted that the risk factor for radiological and symptomatic hyperperfusion in adult MMD was an increase in the preoperative cerebral blood volume (CBV), as assessed using positron emission tomography (PET). The preoperative onset type and the decrease in CBF were not significant factors. Although the PET study is available only at a limited number of centers, a large-scale investigation of parameters other than the CBF, including the CBV, in pediatric MMD may shed light on the factors that contribute to this characteristic postoperative condition. On the other hand, the occurrence of symptomatic hyperperfusion in their series occurred on the left side in 10 of 13 hemispheres (76.9%) after surgery, and the same proportion of patients had a high rate of symptoms that were related to language function, such as aphasia and dysarthria. Although there are differences in age between adult and pediatric cases, it was noteworthy that aphasia appeared in all of the patients in our series. On the other hand, in the investigation by Lu et al. of the prediction of postoperative TNDs, left-sided surgery was a significant

![Image](https://example.com/image.png)

**FIG. 2.** Symptomatic hyperperfusion after left combined revascularization in a 12-year-old patient with MMD. **A:** No stroke lesions were found on MRI (left). On MRA, the bilateral internal carotid artery was highly stenotic at the terminal portion, and the ACA and MCA had disappeared (right). MMVs were bilaterally developed, and the PCA was not affected. **B:** On fluid-attenuated inversion recovery MRI, no new stroke events had occurred, but a sulcal hyperintensity signal had appeared, mainly around the anastomotic site in the frontal lobe (left, red dotted ellipse). An MRA showed an apparent visualization of the STA graft (right, white arrow). **C:** On SPECT performed on POD 3, findings of focal hyperemia were observed on the left frontotemporal lobe, and the patient was diagnosed with symptomatic hyperperfusion (yellow circle).

| Case No. | Preoperative | Postoperative | Focal CBF Increase* | ∆RCBF in This Study† |
|---------|--------------|---------------|---------------------|----------------------|
|         | Vascular Territory Supplied by Bypass | Ipsilateral Cerebellum | Vascular Territory Supplied by Bypass | Ipsilateral Cerebellum |
| 1       | 55.3         | 51.5          | 76.3                | 50.3                | 1.38 | 1.41 |
| 2       | 50.8         | 50.7          | 60                  | 46.3                | 1.18 | 1.29 |
| 3       | 37.9         | 40.5          | 67.6                | 54.9                | 1.78 | 1.32 |
| 4       | 50.5         | 37            | 56                  | 38.9                | 1.11 | 1.05 |
| 5       | 58.6         | 52.8          | 55.7                | 44.6                | 0.95 | 1.13 |
| 6       | 49.7         | 55.1          | 59.7                | 53.1                | 1.2  | 1.25 |
| 7       | 56.5         | 46.8          | 55.6                | 42.5                | 0.98 | 1.08 |

* As calculated by Tashiro et al.
† For the ROI that was supplied by the bypass, we calculated the radioactivity count divided by that count of the ipsilateral cerebellar ROI. This value was defined as the RCBF. The proportional change in the RCBF (denoted ∆RCBF) within each ROI before surgery and on POD 3 was calculated by dividing the postoperative RCBF by the preoperative RCBF.
factor in their multivariate analysis (odds ratio, 2.9). Although their study reported only on adult patients with MMD, their findings are still important as evidence to support the occurrence of events with left-sided surgery in pediatric patients with MMD who are less likely to have postoperative symptomatic hyperperfusion. In their discussion, the verbal symptoms were present for a longer period of time than the other symptoms (mean duration 4 vs. 2 days, respectively), which was consistent with our study (mean, 7 days). We agree with the speculation that function language is susceptible to changes in CBF and is associated with revascularization. All three of our patients were right-handed, and it is expected that the dominant left hemisphere had verbal function. Therefore, the period of onset of verbal symptoms may also be prolonged. The development of COS was a characteristic nonverbal symptom in this series and was observed in two of three of the patients. According to a report from Sasamori et al.,24 this symptom occurred transiently with a frequency of 22.9% after direct and indirect combined revascularization, and their study included one pediatric case. The duration of COS was approximately 7 days, which is similar to our report. However, they reported that no local hyperemia was observed on postoperative SPECT, concluding that COS is caused by other mechanisms. Their consideration of the MRA findings after surgery was unique. They observed preoperative and postoperative changes in the MMVs that had developed in the basal ganglia and thalamus and found that they were rapidly diminishing postoperatively. On the other hand, regarding the neurological symptoms, in a small series of cases involving COS and motor weakness, those symptoms were due to cerebral infarction of the border of the posterior limb of the internal capsule and corona radiata.30 From that fact, it was speculated that COS in MMD patients was also due to transient blood flow disorders around the internal capsule and corona radiata.24 Moreover, 60% of pediatric patients with MMD have been reported to begin experiencing the disappearance of MMVs 1 month after surgery, which begins within 6 months in adult patients.31,32 Their group previously experienced a case of cerebral infarction in the ACA territory due to obstructive changes in the carotid fork due to bypass flow from the STA graft.33 After these considerations, it was speculated that the blood flow of the internal capsule and corona radiata, which are mainly controlled by MMVs, may be impaired by the rapid conversion that is created by the direct bypass in patients with MMD. This rapid conversion from the internal carotid system to the EC system has developed and that the MMVs on the left side had regressed (left). No new stroke was found until it developed as a chronic phase on MRI (right).
diseases other than MMD, it is common to use the ipsilateral cerebellar ratio (RCBF) of the target territory, which is not affected by crossed cerebellar diaschisis.\textsuperscript{15,40} Third, evaluating only the RCBF values after surgery does not take into consideration the changes from the preoperative ischemic state, and as a result, these values may not reflect the pathophysiology of hyperperfusion. Based on the above considerations, we calculated the proportional change (ΔRCBF). Although the results were obtained in three patients, a relatively stable ΔRCBF was calculated for the characteristic symptomatic hyperperfusion pathology compared with the other methodologies (range, 1.29–1.41). Moreover, the average ΔRCBF in the asymptomatic group was 1.13 (range, 1.05–1.25), which was lower than that in the symptomatic group. These data are promising and suggest that the symptoms may have been strongly associated with hyperperfusion. Furthermore, the ΔRCBF calculated by other methods for asymptomatic patients shown in Table 2 (case 4–7) was unstable (range, 0.95–1.2), as were the values for the symptomatic cases. We are convinced that this methodology can be applied not only to pediatric patients with MMD who have had direct bypass but also to adult patients. On the other hand, although the POD 3 protocol is set up at this facility, the ΔRCBF value that predicts radical hyperperfusion will change depending on the timing of the postoperative SPECT imaging (e.g., POD 0–7).

Postoperative management for this condition should be considered. Several treatment strategies for hyperperfusion occurring in adult patients with MMD have been proposed.\textsuperscript{13,16} However, no effective method has been shown for hyperperfusion in pediatric cases. Even drugs that can be used for adults are difficult to give to pediatric patients due to a lack of evidence for their use in children. At least for the patients described in this study, the blood pressure management and fluid therapy strategy that we used were able to prevent the development of hemorrhagic stroke.\textsuperscript{20,22,23,41} In short, the upper limit of the blood pressure is the additional 20% of the preoperative value, and the lower limit is the preoperative baseline blood pressure. The recommended amount of fluid replacement is 1 to 1.5 times the normal maintenance rate. Furthermore, the total balance between oral intake, total infusion volume and urine output should not be negative values. However, this strategy is an empirical treatment that has been utilized in a few cases, and the level of evidence is not high. Therefore, verification by accumulating a large number of case data will be needed.

Lessons

For this rare condition that develops early after surgery, an accurate diagnosis is required by observing focal hyperemia on SPECT. One indicator can be that ΔRCBF has risen to approximately 1.3 or higher. Subsequently, strict blood pressure control and fluid management could prevent the development of hemorrhagic stroke.

References

1. Kuroda S, Houkin K. Moyamoya disease: current concepts and future perspectives.\textit{Lancet Neurol.} 2008;7(11):1056–1066.
2. Suzuki J, Takaku A. Cerebrovascular “moyamoya” disease. Disease showing abnormal net-like vessels in base of brain.\textit{Arch Neurol.} 1969;20(3):288–299.
3. Kim T, Oh CW, Bang JS, Kim JE, Cho WS. Moyamoya disease: treatment and outcomes.\textit{J Stroke.} 2016;18(1):21–30.
4. Kuroda S, Nakayama N, Yamamoto S, et al. Late (5-20 years) outcomes after STA-MCA anastomosis and encephalo-duro-myo-arterio-pericranial synangiosis in patients with moyamoya disease.\textit{J Neurosurg.} 2020;134(3):909–916.
5. Miyamoto S, Yoshimoto T, Hashimoto N, et al. Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan Adult Moyamoya Trial.\textit{Stroke.} 2014;45(5):1415–1421.
6. Zheng J, Yu LB, Dai KF, Zhang Y, Wang R, Zhang D. Clinical features, surgical treatment, and long-term outcome of a multicenter cohort of pediatric moyamoya.\textit{Front Neurol.} 2019;10:14.
7. Araki Y, Uda K, Yokoyama K, et al. Surgical designs of revascularization for moyamoya disease: 15 years of experience in a single center.\textit{World Neurosurg.} 2020;139:e325–e334.
8. Kuroda S, Houkin K. Bypass surgery for moyamoya disease: concept and essence of surgical techniques.\textit{Neural Med Chr (Tokyo).} 2012;52(5):267–294.
9. Kuroda S, Houkin K, Ishikawa T, Nakayama N, Iwasaki Y. Novel bypass surgery for moyamoya disease using pericranial flap: its impacts on cerebral hemodynamics and long-term outcome.\textit{Neurosurgery.} 2010;66(6):1093–1101.
10. Fujimura M, Kaneta T, Mugikura S, Shimizu H, Tominaga T. Temporaty neurologic deterioration due to cerebral hyperperfusion after superficial temporal artery-middle cerebral artery anastomosis in patients with adult-onset moyamoya disease.\textit{Surg Neurol.} 2007;67(3):273–282.
11. Fujimura M, Nizuma K, Endo H, et al. Quantitative analysis of early postoperative cerebral blood flow contributes to the prediction and diagnosis of cerebral hyperperfusion syndrome after revascularization surgery for moyamoya disease.\textit{Neuro Res.} 2015;37(2):131–138.
12. Fujimura M, Tominaga T. Significance of cerebral blood flow analysis in the acute stage after revascularization surgery for moyamoya disease.\textit{Neural Med Chr (Tokyo).} 2015;55(10):775–781.
13. Fujimura M, Nizuma K, Inoue T, et al. Minocycline prevents focal neurologic deterioration due to cerebral hyperperfusion after extracranial-intracranial bypass for moyamoya disease.\textit{Neurosurgery.} 2014;74(2):163–170.
14. Fujimura M, Shimizu H, Inoue T, Mugikura S, Saito A, Tominaga T. Significance of focal cerebral hyperperfusion as a cause of transient neurologic deterioration after extracranial-intracranial bypass for moyamoya disease: comparative study with non-moyamoya patients using N-isopropyl-p-[123]I]iodoamphetamine single-photon emission computed tomography.\textit{Neurosurgery.} 2011;68(4):957–965.
15. Uchino H, Kuroda S, Hirata K, Shiga T, Houkin K, Tamaki N. Predictors and clinical features of postoperative hyperperfusion after surgical revascularization for moyamoya disease: a serial single photon emission CT/positron emission tomography study.\textit{Stroke.} 2012;43(10):2610–2616.
16. Uchino H, Nakayama N, Kazumata K, Kuroda S, Houkin K. Edaravone reduces hyperperfusion-related neurological deficits in adult moyamoya disease: historical control study.\textit{Stroke.} 2016;47(7):1930–1932.
17. Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, Health Labour Sciences Research Grant for Research on Measures for Intractable Diseases. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis).\textit{Neural Med Chr (Tokyo)}. 2012;52(5):245–266.
18. Araki Y, Uda K, Yokoyama K, et al. Challenging direct bypass surgery for very young children with moyamoya disease: technical notes.\textit{Neurosurg Rev.} Published online October 31, 2021. doi: 10.1007/s10143-021-01685-0.
19. Tashiro R, Fujimura M, Katsuki M, et al. Prolonged/delayed cerebral hyperperfusion in adult patients with moyamoya disease with RNF213 gene polymorphism c.14576G→A (rs112735431) after
superficial temporal artery-middle cerebral artery anastomosis. J Neurosurg. 2021;135(2):417–424.

20. Araki Y, Uda K, Yokoyama K, et al. Risk factors for cerebral infarction early after revascularization in children younger than 5 years with moyamoya disease. World Neurosurg. Published online January 4, 2022. doi: 10.1016/j.wneu.2021.12.115.

21. Araki Y, Yokoyama K, Uda K, et al. Postoperative stroke and neurological outcomes in the early phase after revascularization surgeries for moyamoya disease: an age-stratified comparative analysis. Neurosurg Rev. 2021;44(5):2785–2795.

22. Muraoka S, Araki Y, Kondo G, et al. Postoperative cerebral infarction risk factors and postoperative management of pediatric patients with moyamoya disease. World Neurosurg. 2018;113:e190–e199.

23. Uda K, Araki Y, Muraoka S, et al. Intraoperative evaluation of local cerebral hemodynamic change by indocyanine green videoangiography: prediction of incidence and duration of postoperative transient neurological events in patients with moyamoya disease. J Neurosurg. Published online April 20, 2018. doi:10.3171/2017.10. JNS171523.

24. Sasamoto T, Kuroda S, Nakayama N, Iwasaki Y. Incidence and pathogenesis of transient cheiro-oral syndrome after surgical revascularization for moyamoya disease. Neurosurgery. 2010;67(4):1054–1060.

25. Fujimura M, Tominaga T. Lessons learned from moyamoya disease: outcome of direct/indirect revascularization surgery for 150 affected hemispheres. Neurul Med Chir (Tokyo). 2012;52(5):327–339.

26. Ishikawa T, Yamaguchi K, Kawashima A, et al. Predicting the occurrence of hemorrhagic cerebral hyperperfusion syndrome using regional cerebral blood flow after direct bypass surgery in patients with moyamoya disease. World Neurosurg. 2018;119:e750–e756.

27. Hayashi T, Shirane R, Fujimura M, Tominaga T. Postoperative neurological deterioration in pediatric moyamoya disease: watershed shift and hyperperfusion. J Neurosurg Pediatr. 2010;6(1):73–81.

28. Rashad S, Fujimura M, Nizuma K, Endo H, Tominaga T. Long-term follow-up of pediatric moyamoya disease treated by combined direct-indirect revascularization surgery: single institute experience with surgical and perioperative management. Neurosurg Rev. 2016;39(4):615–623.

29. Lu J, Zhao Y, Ma L, et al. Predictors and clinical features of transient neurological events after combined bypass revascularization for moyamoya disease. Clin Neurol Neurosurg. 2019;186:105505.

30. Isono O, Kawamura M, Shiota J, Araki S, Hirayama K. Cheiro-oral topography of sensory disturbances due to lesions of thalamocortical projections. Neurology. 1993;43(4):1:51–55.

31. Houkin K, Kamiyama H, Abe H, Takahashi A, Kuroda S. Surgical therapy for adult moyamoya disease. Can surgical revascularization prevent the recurrence of intracerebral hemorrhage? Stroke. 1996;27(8):1342–1346.

32. Houkin K, Nakayama N, Kuroda S, Ishikawa T, Nonaka T. How does angiogenesis develop in pediatric moyamoya disease after surgery? A prospective study with MR angiography. Childs Nerv Syst. 2004;20(10):734–741.

33. Kuroda S, Houkin K, Nunomura M, Abe H. Frontal lobe infarction due to hemodynamic change after surgical revascularization in moyamoya disease–two case reports. Neurol Med Chir (Tokyo). 2000;40(6):315–320.

34. Tashiro R, Fujimura M, Kameyama M, et al. Incidence and risk factors of the watershed shift phenomenon after superficial temporal artery-middle cerebral artery anastomosis for adult moyamoya disease. Cerebrovasc Dis. 2019;47(3-4):178–187.

35. Tu XK, Fujimura M, Rashad S, et al. Uneven cerebral hemodynamic change as a cause of neurological deterioration in the acute stage after direct revascularization for moyamoya disease: cerebral hyperperfusion and remote ischemia caused by the ‘watershed shift’. Neurosurg Rev. 2017;40(3):507–512.

36. Yu J, Hu M, Yi L, Zhou K, Zhang J, Chen J. Paradoxical association of symptomatic cerebral edema with local hyperperfusion caused by the ‘watershed shift’ after revascularization surgery for adult moyamoya disease: a case report. Ther Adv Neurol Disord. Published online September 25, 2019. doi: 10.1177/1756286419878343.

37. Aihara Y, Kashiwase S, Chiba K, et al. Aspirin use and platelet aggregation in ischemic onset-type pediatric moyamoya patients with intracerebral eadg (moya-ache). Childs Nerv Syst. 2021;37(5):1649–1657.

38. Kameyama M, Fujimura M, Tashiro R, et al. Significance of quantitative cerebral blood flow measurement in the acute stage after revascularization surgery for adult moyamoya disease: implication for the pathological threshold of local cerebral hyperperfusion. Cerebrovasc Dis. 2018;46(3-6):217–225.

39. Ishiguro T, Okada Y, Ishikawa T, Yamaguchi K, Kawashima A, Kawamata T. Efficacy of superficial temporal artery-middle cerebral artery double bypass in patients with hemorrhagic moyamoya disease: surgical effects for operated hemispheric sides. Neurosurg Rev. 2019;42(2):559–568.

40. Ito H, Kanno I, Shimosegawa E, Tamura H, Okane K, Hatazawa J. Hemodynamic changes during neural deactivation in human brain: a positron emission tomography study of crossed cerebellar diaschisis. Ann Nucl Med. 2002;16(4):249–254.

41. Araki Y, Yokoyama K, Uda K, et al. Paradoxical symptomatic cerebral blood flow decreases after combined revascularization surgery for patients with pediatric moyamoya disease: illustrative case. J Neurosurg Case Lessons. 2022;23(3):CASE21628.

Disclosures
The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Author Contributions
Conception and design: Araki, Mamiya, Takayanagi, Nishihori, Kato. Acquisition of data: Araki, Mamiya, Fujita, Yokoyama, Uda, Kanamori, Takayanagi, Nishihori, Nagata, Izumi, Kato. Analysis and interpretation of data: Araki, Mamiya, Takayanagi, Tanahashi, Muraoka, Kato. Drafting the article: Araki, Takayanagi. Critically revising the article: Ishii, Nishihori, Tanahashi, Izumi, Saito. Reviewed submitted version of manuscript: Yokoyama, Uda, Kanamori, Takeuchi, Tanahashi, Nagata, Nishimura, Saito. Approved the final version of the manuscript on behalf of all authors: Araki. Administrative/technical/material support: Fujita, Uda, Nishimura, Tanei, Muraoka, Kato. Study supervision: Nishihori, Tanei, Saito.

Correspondence
Yoshio Araki: Nagoya University Graduate School of Medicine, Aichi, Japan. y.araki@med.nagoya-u.ac.jp.